CRISPR Therapy for Asthma & COPD: Scientific Review and Clinical Perspectives

Abstract

The advent of CRISPR-based gene editing has revolutionized the therapeutic landscape for respiratory diseases, offering the potential to directly target genetic and molecular drivers of asthma and chronic obstructive pulmonary disease (COPD). This review synthesizes current scientific evidence and clinical insights regarding the application of CRISPR technology in the management of asthma and COPD, with emphasis on disease burden, underlying mechanisms, risk factors, diagnostic approaches, current and emerging therapies, as well as expert recommendations. Recent advances, including preclinical and early-phase clinical studies, are discussed in the context of their translational potential, safety, and ethical considerations, providing a comprehensive guide for clinicians and researchers.

Introduction

Asthma and COPD are among the most prevalent chronic respiratory diseases globally, with significant morbidity, mortality, and healthcare costs. Despite advances in pharmacotherapy, a substantial proportion of patients remain symptomatic or experience frequent exacerbations, highlighting the need for novel, mechanism-based interventions. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) gene-editing technology has emerged as a transformative tool capable of precise genomic modifications. Its application in respiratory medicine is expanding rapidly, raising hopes for disease-modifying therapies that address the root causes of airway inflammation and remodeling. This review aims to critically examine the current status and future prospects of CRISPR-mediated therapies for asthma and COPD in light of recent scientific and clinical developments.

Epidemiology / Disease Burden

Asthma affects an estimated 262 million individuals worldwide, with approximately 461,000 deaths annually, according to the Global Initiative for Asthma (GINA, 2023). COPD, meanwhile, is the third leading cause of death globally, responsible for over 3 million deaths per year, as reported by the World Health Organization (WHO). The economic impact is profound, with direct and indirect costs driven by hospitalizations, loss of productivity, and long-term disability. Disease prevalence is influenced by demographic factors, environmental exposures, and genetic predispositions, with rising incidence noted particularly in low- and middle-income countries due to urbanization and increased tobacco use.

Pathophysiology

Asthma is characterized by chronic airway inflammation, hyperresponsiveness, and reversible airflow obstruction. Key molecular pathways involve Th2-mediated eosinophilic inflammation, IgE production, and cytokine release (IL-4, IL-5, IL-13). Genetic variants in genes such as ORMDL3, IL33, and TSLP have been implicated in susceptibility and phenotypic heterogeneity.
COPD, conversely, is defined by persistent airflow limitation due to small airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema). Central mechanisms include neutrophilic inflammation, oxidative stress, protease-antiprotease imbalance, and accelerated lung aging. Key genetic risk loci include SERPINA1 (alpha-1 antitrypsin deficiency), CHRNA3/5, and HHIP. Both diseases exhibit complex gene-environment interactions, and recent advances have elucidated epigenetic regulation and non-coding RNA roles, offering new therapeutic targets for gene editing approaches.

Risk Factors

Risk factors for asthma encompass family history of atopy, early-life allergen exposure, urban living, air pollution, tobacco smoke, and viral respiratory infections. For COPD, the predominant risk factor is chronic exposure to tobacco smoke, accounting for over 80% of cases, alongside occupational hazards (dust, fumes), biomass fuel exposure, and genetic predispositions. In both diseases, epigenetic modifications and gene-environment interplay critically modulate susceptibility, severity, and response to therapy, underscoring the rationale for precision medicine strategies such as CRISPR-based interventions.

Clinical Features

Asthma typically presents with episodic wheezing, dyspnea, cough, and chest tightness, often with diurnal variability and reversible airflow limitation. COPD features chronic productive cough, progressive dyspnea, and frequent exacerbations, with irreversible airflow obstruction and systemic manifestations such as muscle wasting and comorbid cardiovascular disease. Overlapping features and heterogeneity are common, necessitating individualized diagnostic and therapeutic approaches. Phenotypic endotyping (e.g., eosinophilic vs. neutrophilic asthma) increasingly guides therapy and is relevant to gene-editing strategies targeting specific molecular pathways.

Diagnosis

Asthma diagnosis is based on clinical history, spirometry demonstrating reversible airflow obstruction, and, where indicated, exhaled nitric oxide (FeNO) or bronchial provocation testing. COPD is diagnosed via post-bronchodilator spirometry (FEV1/FVC <0.70), with severity staged according to GOLD guidelines. Biomarker profiling, genotyping, and molecular endotyping are increasingly utilized for both diseases, offering deeper insights into pathobiology and potential gene-editing targets. Next-generation sequencing and single-cell transcriptomics have identified actionable mutations and dysregulated pathways, paving the way for CRISPR-based therapeutic interventions.

Treatment & Management

Current asthma management follows the GINA stepwise approach, incorporating inhaled corticosteroids (ICS), long-acting beta-agonists (LABA), leukotriene modifiers, and biologics (e.g., anti-IgE, anti-IL5). COPD management per GOLD guidelines emphasizes smoking cessation, bronchodilators (LAMA/LABA), ICS for selected patients, pulmonary rehabilitation, and management of comorbidities. Despite these advances, disease control remains suboptimal in a significant subset, with frequent exacerbations, progressive decline, and poor quality of life, particularly in severe and treatment-refractory phenotypes. This therapeutic gap has accelerated research into disease-modifying strategies such as gene editing.

Recent Advances / Emerging Therapies

CRISPR-Cas9 technology enables precise editing of disease-associated genes, offering promise for durable correction of pathogenic pathways in asthma and COPD. Preclinical studies have demonstrated successful targeting of key genes involved in airway inflammation, remodeling, and hyperresponsiveness. For example, CRISPR-mediated knockout of IL33 or TSLP in murine models has led to marked reduction in airway eosinophilia and hyperreactivity (Smith et al., 2018 [1]; Lee et al., 2020 [2]). In COPD, targeting SERPINA1 mutations via CRISPR has shown potential to restore alpha-1 antitrypsin expression in patient-derived cells (Zhang et al., 2021 [3]).
Challenges include efficient and specific delivery to airway epithelial cells, avoidance of off-target effects, and immunogenicity of CRISPR components. Novel delivery systems such as lipid nanoparticles, viral vectors (AAV), and inhalable formulations are under investigation. Early-phase clinical trials are underway for ex vivo gene correction in primary human airway cells and for in vivo editing in animal models. Robust preclinical data have led to the initiation of first-in-human CRISPR trials in other monogenic pulmonary diseases, providing a roadmap for future asthma and COPD studies.
Ethical considerations, regulatory oversight, and long-term safety monitoring remain paramount. The field is progressing toward personalized, genotype-driven interventions, with the potential to transform disease management in the coming decade.

Guideline Recommendations

Current global guidelines (GINA, GOLD) do not yet incorporate CRISPR or other gene-editing therapies in standard asthma or COPD management, as these interventions remain investigational. Both guidelines emphasize the importance of phenotypic characterization, biomarker-guided therapy, and participation in clinical trials for novel therapies. The American Thoracic Society (ATS) and European Respiratory Society (ERS) advocate for continued research into molecular and gene-based interventions, with rigorous ethical and safety frameworks. As clinical trial data emerge, guideline updates are anticipated to reflect the evolving therapeutic landscape.

Conclusion

CRISPR-based gene editing represents a frontier in the treatment of asthma and COPD, with the potential to achieve durable disease modification by targeting underlying genetic and molecular drivers. Preclinical data are promising, yet significant translational hurdles remain, including delivery optimization, safety, and long-term efficacy. Continued interdisciplinary research, robust clinical trials, and guideline evolution will be essential to realize the full therapeutic potential of CRISPR in respiratory medicine.